This site uses cookies as described in our Privacy Notice. Please click Accept if you agree to the use of cookies on our site. Accept OUR MISSION G1 is committed to improving the lives of those impacted by cancer. Led by a team with a deep understanding of the biology of cancer and extensive development and commercialization expertise, G1 is advancing its mission by commercializing the first and only proactive multilineage myeloprotection therapy, COSELA™ (trilaciclib). G1 is also executing a tumor-agnostic development program, with late-stage clinical trials ongoing in multiple tumor types including colorectal, breast, lung, and bladder cancers. Our Mission Our Leadership Board of Directors Collaborations Social Responsibility Our Company Our Product Our Science Patients Careers Investors News Medical Professionals Contact Home ©2021 G1 Therapeutics, Inc. All rights reserved.Website design: Hane Chow, Inc. LinkedIn Twitter Privacy Policy Cookie Policy Terms of Use

This site uses cookies as described in our Privacy Notice. Please click Accept if you agree to the use of cookies on our site. BOARD OF DIRECTORS Board of Directors Jack Bailey Chief Executive Officer, G1 Therapeutics Willie Deese Chair, Nominating and Governance Committee; Audit Committee Cynthia Flowers Chair, Compensation Committee; Nominating and Governance Committee Glenn P. Muir Chair, Audit Committee; Compensation Committee Garry Nicholson, Chair Board Chair; Audit Committee; Nominating and Governance Committee Alicia Secor Compensation Committee Mark Velleca, M.D., Ph.D. Senior Advisor Our Mission Our Leadership Board of Directors Collaborations Social Responsibility Our Company Our Product Our Science Patients Careers Investors News Medical Professionals Contact Home ©2021 G1 Therapeutics, Inc. All rights reserved.Website design: Hane Chow, Inc. LinkedIn Twitter Privacy Policy Cookie Policy Terms of Use